Rabacfosadine

Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs.^[1] It was developed by Gilead Sciences as GS-9219.^[2]

Rabacfosadine

Clinical data
Trade names	Tanovea
Other names	GS-9219
AHFS/Drugs.com	Veterinary Use
License data	US DailyMed: Rabacfosadine
Routes of administration	Intravenous
ATCvet code	QL01BB90 (WHO)
Legal status
Legal status	US: ℞-only[1]
Identifiers
CAS Number	859209-74-8
PubChem CID	16047979
DrugBank	DB12762
ChemSpider	4486268
UNII	M39BO43J9W
KEGG	D10723
ChEMBL	ChEMBL1823518
CompTox Dashboard (EPA)	DTXSID10235245
Chemical and physical data
Formula	C11H35N8O6P
Molar mass	406.425 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC( = O)[C@H](C)NP( = O)(COCCN1C = NC2 = C1N = C(N = C2NC3CC3)N)N[C@@H](C)C( = O)OCC
InChI InChI=1S/C21H35N8O6P/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26)/t13-,14-/m0/s1 Key:ANSPEDQTHURSFQ-KBPBESRZSA-N

The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases. In vitro studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.^[3] It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.^[4]

Rabacfosadine was granted conditional approval by the US Food and Drug Administration (FDA) in December 2016,^[5] and became the first medication to receive full approval for the treatment of canine lymphoma in July 2021.^[6]

Veterinary uses

In July 2021, the U.S. Food and Drug Administration (FDA) approved Tanovea to treat lymphoma in dogs.^[6] Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs.^[6] Rabacfosadine is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval.^[6]

Adverse effects

Common side effects of rabacfosadine are decreased white blood cell count, diarrhea, vomiting, decreased appetite or loss of appetite, weight loss, decreased activity level, and skin problems. Other side effects may occur.^[5]